Evidence map›Paper›PMID 30332421›Full record

ArticlePLoS neglected tropical diseases2018

What motivates Ebola survivors to donate plasma during an emergency clinical trial? The case of Ebola-Tx in Guinea.

Maya Ronse, Almudena Marí Sáez, Charlotte Gryseels, Melanie Bannister-Tyrrell, Alexandre Delamou, Alain Guillard, Mustapha Briki, Frédéric Bigey, Nyankoye Haba, Johan van Griensven and 1 more

Abstract readComparative Study
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maya RonseDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0001-7182-6940
Almudena Marí SáezDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Charlotte GryseelsDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Melanie Bannister-TyrrellDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Alexandre DelamouDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Alain GuillardCollecte et Production des PSL, Établissement Français Du Sang Bretagne, Rennes, France.
Mustapha BrikiÉtablissement Français Du Sang Alpes-Méditerranée, Marseille, France.
Frédéric BigeyDirection, Établissement Français du Sang Grand-Est, Strasbourg, France.ORCID 0000-0002-7424-429X
Nyankoye HabaCentre National de Transfusion Sanguine (National Blood Transfusion Centre), Conakry, Guinea.
Johan van GriensvenDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Koen Peeters GrietensDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDuring the 2014 Ebola Virus Disease (EVD) epidemic, the Ebola-Tx trial evaluated the use of convalescent plasma (CP) in Guinea. The effectiveness of plasmapheresis trials depends on the recruitment of plasma donors. This paper describes what motivated or deterred EVD survivors to donate CP, providing insights for future plasmapheresis trials and epidemic preparedness.

methodsThis qualitative study, part of Ebola-Tx, researched and addressed emergent trial difficulties through interviewing, participant observation and focus group discussions. Sampling was theoretical and retroductive analysis was done in NVivo 10.

resultsWillingness or hesitance to participate in plasma donation depended on factors at the interface of pre-existing social dynamics; the impact of the disease and the consequent emergency response including the trial set-up. For volunteers, motivation to donate was mainly related to the feeling of social responsibility inspired by having survived EVD and to positive perceptions of plasmapheresis technology despite still unknown trial outcomes. Conversely, confidentiality concerns when volunteering due to stigmatization of survivors and perceived decrease in vital strength and in antibodies when donating, leading to fears of loss in protection against EVD, were main deterrents. The dynamic (dis)trust in Ebola Response Actors and in other survivors further determined willingness to participate and lead to the emergence/decline of rumours related to blood stealing and treatment effectiveness. Historic inter-ethnic relations in the health care setting further defined volunteering along socio-economic and ethnic lines. Finally, lack of follow-up and of dedicated care further impacted on motivation to volunteer.

conclusionsEbola-Tx was the first trial to solicit and evaluate blood-product donation as an experimental treatment on a large scale in Sub-Saharan Africa. An effective donation system requires directly engaging with emergent social barriers and providing an effective ethical response, including improved and transparent communication, effective follow-up after donation, assuring confidentiality and determining ethical incentives.

Indexed as

AdultBlood DonorsFemaleGuineaHemorrhagic Fever, EbolaHumansImmunization, PassiveInterviews as TopicMalePatient ParticipationPlasmapheresisSurvivors

Identifiers

PMID30332421
PMCPMC6219816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.